Easy returns policy
Reimbursement for a product return will only be issued to the appropriate party in the form of replacement product. Replacement product will be issued only if it is pre-authorized and only after the product has been received and identified by McKesson.
Shipment paperwork for product returns must indicate the following:
- Debit memo number (if applicable)
- DEA number of sender
- Return authorization number
- Reason for return
- Product information
- Product name
- Lot number
- Expiration date
Product returns will only be accepted from authorized accounts (including healthcare providers and wholesalers) under the following circumstances:
- Product with 8 weeks prior to expiration date, or up to 6 months past expiration
- Product was discontinued, withdrawn, or recalled by manufacturer
- Product was damaged in transit (notice must be given within 2 business days of receipt of shipment)
- Product was shipped in error
Product must be in its original container.
All products not meeting the conditions listed above shall be deemed nonreturnable. In addition, products listed below are not returnable:
- Product received or purchased from unauthorized distributors
- Product with more than 8 weeks prior to expiration date, or more than 6 months past expiration date
- Packages with removed labels or broken seals
- Repackaged product
- Product that has been in a fire, clearance, bankruptcy, or similar sale
- Product sold on a “non-returnable” basis
- Reconstituted product
- Product purchased or otherwise obtained in violation of any federal, state, or local law regulation
- Product that has been destroyed or damaged from events such as fire, water, tornado, or catastrophe
- Product that has deteriorated due to improper storage or handling
For all product return requests, call 1-888-525-2423 for authorization. Ipsen will provide an authorization number and issue the appropriate forms and labels to you. Return authorizations are valid for a period of 90 days past their issue date, after which time returns will be considered unauthorized, and destroyed without credit.
Terms are subject to change at any time without notice.
Dysport is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients.
Important Safety Information
Distant Spread of Toxin Effect: Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.
Dysport is contraindicated in patients with hypersensitivity to any botulinum toxin product or its excipients, including human albumin, lactose, and cow's milk protein, or who have an infection at the proposed injection site.
The potency Units of Dysport are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of Dysport cannot be compared to or converted into Units of any other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded.
Immediate medical attention may be required in cases of respiratory, speech, or swallowing difficulties. Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Concomitant neuromuscular disorder may exacerbate clinical effects of treatment.
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including severe dysphagia and respiratory compromise from typical doses of Dysport.
Dysport contains human albumin. Based on effective donor screening and product manufacturing processes, Dysport carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.
The possibility of an immune reaction when injected intradermally is unknown. The safety of Dysport for the treatment of hyperhidrosis has not been established.
Patients receiving concomitant treatment of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of botulinum toxin may be potentiated. Use of anticholinergic drugs may potentiate systemic anticholinergic effects. The effect of administering different botulinum neurotoxins during the course of treatment with Dysport is unknown.
There are no adequate and well-controlled studies in pregnant women. Dysport should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The most commonly observed adverse reactions (>5% of patients) with Dysport for the treatment of cervical dystonia are muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.
To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Ipsen at 1-877-397-7671 (877- DYSPOR1). You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
All trademarks used herein belong to their respective owners.